Understanding how a specific HIV mutation affects drug sensitivity to Islatravir
Mechanisms of HIV-1 Hypersensitivity to Islatravir
This study is looking at how a certain change in the HIV-1 virus makes it easier for a new long-lasting medication called Islatravir to work, especially for people with HIV-1 who might struggle with sticking to their treatment.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10843946 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which a specific mutation in the HIV-1 virus makes it more sensitive to Islatravir, a long-acting antiviral medication. The study focuses on patients with HIV-1 who may experience drug resistance due to non-adherence to treatment regimens. By examining the structural changes caused by the F227C mutation in the virus, researchers aim to improve the effectiveness of Islatravir when used in combination with other antiviral drugs. This could lead to better treatment options for patients living with HIV-1.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV-1, particularly those who have experienced issues with drug resistance or non-adherence to treatment.
Not a fit: Patients who are not infected with HIV-1 or those who have not experienced drug resistance may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for HIV-1, reducing the risk of drug resistance and improving patient outcomes.
How similar studies have performed: Previous research has shown that understanding viral mutations can lead to significant advancements in antiviral therapies, suggesting potential success for this approach.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Snyder, Alexa Anne — Emory University
- Study coordinator: Snyder, Alexa Anne
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.